Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2

Status

Completed 190Recruiting 130Terminated 86Active not recruiting 71Unknown 69Withdrawn 22Not yet recruiting 16Enrolling by invitation 4Suspended 2Available 2Approved for marketing 2

Sponsor Class

OTHER 4

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 2Breast 2

Conditions

Neoplasms 73Breast Neoplasms 70Colorectal Neoplasms 39Prostatic Neoplasms 37Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 25Stomach Neoplasms 20Carcinoma, Hepatocellular 20Uterine Cervical Neoplasms 19Pancreatic Neoplasms 15Anxiety Disorders 15Leukemia, Myeloid, Acute 14Hematologic Neoplasms 13Colonic Neoplasms 13Brain Neoplasms 13Urinary Bladder Neoplasms 12Lymphoma, Follicular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Head and Neck Neoplasms 11Esophageal Neoplasms 10Diabetes Mellitus 10Ovarian Neoplasms 9Melanoma 9Liver Neoplasms 9Sarcoma 8Rectal Neoplasms 8Pulmonary Disease, Chronic Obstructive 8Multiple Myeloma 8Esophageal Squamous Cell Carcinoma 8Disease 8

Interventions

Fluorodeoxyglucose F18 2Focus Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Enrolling by invitation × Carcinoma, Transitional Cell × Clear all
NCT07454941 2026-03-06

Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrolling by invitation
4,000 enrolled
Genitourinary

Carcinoma, Transitional Cell, Disease

NCT07091565 2025-08-03

SPARC

King's College London

Enrolling by invitation
60 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07023848 2025-06-17

PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors

Affiliated Hospital of Jiangnan University

Phase EARLY_PHASE1 Enrolling by invitation
10 enrolled
BreastGastrointestinalGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT07023861 2025-06-17

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

Affiliated Hospital of Jiangnan University

Phase EARLY_PHASE1 Enrolling by invitation
20 enrolled
BreastGastrointestinalGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡